Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

Phase I, Open Label, Clinical Study to Determine the Maximum Tolerated Dose (MTD) of Oral Dovitinib (TKI258) When Given in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01680796
• Other study ID #: CTKI258AU012T
• Status: Withdrawn
• Phase: Phase 1
• First received: August 29, 2012
• Last updated: February 18, 2013
• Start date: February 2013
• Est. completion date: February 2013

Study information

• Verified date: February 2013
• Source: University of Florida
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is an open-label phase I study in which dovitinib is given in combination with bortezomib and dexamethasone. Dovitinib dose escalation is planned in order to determine its maximum tolerated dose when given in this combination.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of multiple myeloma

• Karnofsky performance status = 70

• Age = 18 years old

• Evidence of relapsed or refractory disease as documented from the prior treatment history

• Have received at least 1, but not more than 3, prior treatment regimens for multiple myeloma including chemotherapy, autologous stem cell transplantation, immunotherapy, or other investigational agents. Prior allogeneic stem cell transplant and prior therapy with bortezomib (with no evidence of disease resistance to bortezomib) are permitted.

• Last dose of chemotherapy no less than 4 weeks prior to receipt of study medication and have recovered from the side effects of such therapy

• Last dose of biological therapy, or antibody, or other investigational agents, no less than 4 weeks prior to receipt of study medication

• Subjects must have the following laboratory values:

• Absolute neutrophil count (ANC) = 1.5 x 109/L

• Platelets = 100 x 109/L

• Hemoglobin (Hgb) > 9 g/dL

• Serum total bilirubin: = 1.5 x ULN

• ALT and AST = 3.0 x ULN

• Serum creatinine = 1.5 x ULN

• Willing and able to undergo bone marrow aspirates as per protocol, with/without bone marrow biopsy according to the study center's practice. - Life expectancy of = 12 weeks

• All subjects (male and female) of child bearing potential must agree to use adequate contraceptive methods.

• Negative serum pregnancy test (= 72 hours prior to the first dosing of dovitinib) in all women of childbearing potential

• Subjects who give a written informed consent obtained according to local guidelines

Exclusion Criteria:

• Subjects with CNS (central nervous system) disease

• Subjects with another primary malignancy within 3 years prior to starting study drug, with the exception of adequately treated in-situ carcinoma of the uterine cervix, or skin cancer

• Subjects who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosurea, mitomycin-C, targeted therapy and radiation) = 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy

• Subjects who have had radiotherapy = 4 weeks prior to starting study drug, or = 2 weeks prior to starting study drug in the case of localized radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture), or who have not recovered from radiotherapy toxicities

• Subjects who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury = 4 weeks prior to starting study drug, or subjects who have had minor procedures, percutaneous biopsies or placement of vascular access device = 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury

• Subjects with any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:

• Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

1. History or presence of serious uncontrolled ventricular arrhythmias

2. Clinically significant resting bradycardia

3. LVEF assessed by 2-D echocardiogram (ECHO) < 50% or lower limit of normal (whichever is higher) or multiple gated acquisition scan (MUGA) < 45% or lower limit of normal (whichever is higher).

4. Any of the following within 6 months prior to starting study drug:

myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)

5. Uncontrolled hypertension defined by a SBP = 160 mm Hg and/or DBP = 100 mm Hg, with or without anti-hypertensive medication(s),

• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dovitinib (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection),

• Cirrhosis, chronic active hepatitis or chronic persistent hepatitis,

• Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory),

• Subjects who are currently receiving anticoagulation treatment with therapeutic doses of warfarin,

• Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol

• Pregnant or breast-feeding women

• Women of child-bearing potential, who are biologically able to conceive, not willing to employ two forms of highly effective contraception

• Fertile males not willing to use contraception

• Subject has a known hypersensitivity to bortezomib, or known Grade = 2 bortezomib-related neuropathy

• Subjects unwilling or unable to comply with the protocol

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Dovitinib
Dose Level 0: 200 mg daily Dose Level 1: 300 mg daily Dose Level 2: 300 mg daily Dose Level 3: 400 mg daily Dose Level 4: 500 mg daily
• Bortezomib
Dose Level 0: 1.3 mg/m2 IV on days 1 and 8 Dose Level 1: 1.3 mg/m2 IV on days 1 and 8 Dose Level 2: 1.6 mg/m2 IV on days 1 and 8 Dose Level 3: 1.6 mg/m2 IV on days 1 and 8 Dose Level 4: 1.6 mg/m2 IV on days 1 and 8
• Dexamethasone
Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University of Florida	Novartis Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Other Secondary Efficacy Objectives	Participants will be evaluated for time to first response, duration of response, time to best response, and time to disease progression.	Up to 10 years	No
Primary	Evaluate the safety and dose-limiting toxicity of treatment with dovitinib in combination with bortezomib/ dexamethasone.	Determination of the maximum tolerated dose of dovitinib will be based on Treatment Cycle 1 safety data for all subjects for whom all safety assessments during Treatment Cycle 1, as well as the pre-dosing safety assessments performed on Study Day 1 of Treatment Cycle 2, are completed and who do not receive alternate anti-neoplastic therapies during that period.	Treatment Cycle 1 (three weeks) for each participant.	Yes
Secondary	To assess the overall response rate for the combination dovitinib/bortezomib/ dexamethasone in patients receiving at least 4 cycles of therapy.	Starting with Treatment Cycle 2, response to treatment will be determined during each treatment cycle (Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR), and Stable Disease (SD)).	Participants will be followed for up to one year.	No